NCT03284385: WEE1 Inhibitor AZD1775 in Treating Patients With SETD2-Deficient Locally Advanced or Metastatic Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: SETD2
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult), Senior)
Location of Metastases: 
Additional Notes: Tumor must have biallelic loss of SETD2
Exclusions: Unstable untreated brain metastases

Up ↑